Showing 141 - 160 results of 101,316 for search '(( 10 ng decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.49s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144

    Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB. by David M. Mutch (37665)

    Published 2013
    “…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151

    HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression. by Michael Anthony Ruiz (726055)

    Published 2015
    “…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”
  12. 152
  13. 153
  14. 154

    Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

    Published 2022
    “…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
  15. 155
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160